Biosimilar Best Practice Day 21st January 2019 Ricoh Suite, Cardiff City Stadium Procurement Services Medicines (Acute) Sourcing Team Tracey Prothero Senior Category Manager
Medicines (Acute) Sourcing Team Currently a team of 5 people All Wales contract expenditure of £170m (£315m) 2,602 drug lines (25 Framework Contracts) 131 suppliers Savings opportunities created during 2017/18 - £12.1m
Contract Cycle Demand Manage and Review Tender Process Analysis Standstill/ Award Process Contract Implementation Manage and Review
Chief Pharmacists Group Welsh Government Chief Pharmaceutical Officer Health Boards and Velindre Cancer Centre Chief Pharmacists Group NHS Wales Shared Services Partnership Director Procurement Services All Wales Drug Contracting Committee All Wales Medicines Procurement Specialist Pharmacist All Wales Quality Control and Assurance Pharmacist NWSSP Procurement Services Acute Medicine Team Welsh Medicines Procurement and Logistics Advisory Group Clinical Pharmaceutical Technical Services Group Service Users Suppliers
All Wales saving achieved to date: £17.5m Biosimilar Contracts Contracts for the following Biosimilar drugs have been agreed since 2015: Infliximab, Etanercept, Rituximab, Trastuzumab Adalimumab All Wales saving achieved to date: £17.5m
Things to consider when tendering Engagement with other home nations Optimum number of contractors Homecare requirement Data Quality Device for administration Continuity of supply Licensed indications of biosimilar products vs originator product Differing excipients vs originator Consensus meetings – who to involve?
Contract Management Usage monitoring Price benchmarking Ongoing savings reports Homecare - Monitoring Monthly KPI data Regular contract review meetings/Price reviews
What Next? Horizon Scanning Improving Communication and links with clinical teams Take Learning from previous projects to improve and develop future agreements
Questions?